OPTIZIOME® Fructanase® (Inulinase Enzyme for FODMAP Support — BIO-CAT)

Evidence Level
Preliminary
2 Clinical Trials
7 Documented Benefits
1/5 Evidence Score

Optiziome® Fructanase® (formerly Optiziome® Inulinase) is BIO-CAT's fructanase enzyme designed to help digest fructans — a class of FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) found in many vegetables, grains, and fruits that cause digestive discomfort in sensitive individuals. The only published trial was a 4-week randomized, double-blind, placebo-controlled safety and tolerability study in 60 healthy adults with no diagnosed digestive problems, and it found no significant difference in digestive outcomes versus placebo. A safety study measures harm, not benefit, so there is currently no clinical evidence that this enzyme relieves bloating, gas or any other symptom. One important safety point: fructans are carbohydrates and gluten is a protein, so a fructan-digesting enzyme does not make wheat safe for anyone with coeliac disease.

Studied Dose 400 mg twice daily (2,000 inulinase units a day). This is the dose used in the single 4-week safety trial in healthy adults; no dose has been shown to relieve symptoms.
Active Compound Fructanase (inulinase) — non-GMO, wild-type enzyme preparation.

Benefits

FODMAP digestive support (fructan-specific)

Fructans are a specific FODMAP class commonly shared across many fruits and vegetables — including wheat, onions, garlic, asparagus, artichokes, and chicory root. In laboratory conditions the enzyme breaks fructans into shorter chains and free sugars, which in theory means less material reaching the colon to be fermented into gas. That is the proposed mechanism only. The one published human trial did not show any reduction in bloating, gas or abdominal discomfort, so this remains unproven in people. Note also that wheat contains both fructans and gluten. This enzyme acts only on the fructan carbohydrate and does nothing to gluten, so it does not make wheat safe for anyone with coeliac disease or a wheat allergy.

Phase I safety and tolerability validated

Phase I safety and tolerability validated: a randomized double-blind placebo-controlled trial evaluating 2,000 INU/day found the fructanase preparation safe and well tolerated, with no significant differences in GI outcomes vs placebo. The trial was designed to look for harm, not to test whether symptoms improve, and it was run in healthy people, so it cannot tell us whether the enzyme helps anyone feel better.

FDA NDIN-granted regulatory status

Optiziome® Fructanase is one of only six fungal/microbial enzymes in the past decade to receive FDA New Dietary Ingredient Notification (NDIN). This is a regulatory filing, not a health benefit. An NDIN means the FDA received a safety notification for the ingredient and did not object to it. It is not FDA approval, and it says nothing about whether the enzyme does anything for your digestion.

Not yet tested in people who have symptoms

This is a research gap, not a benefit. The authors of the safety trial wrote that further research is warranted to find out whether microbial inulinase can reduce fructan malabsorption, digestive symptoms or intestinal inflammation in people with FODMAP sensitivity or IBS. That research has not been done. Nobody has tested this enzyme in people who actually have digestive symptoms, and a supplement is not a treatment for IBS or any other diagnosed condition.

The hope of eating a wider range of plant foods (untested)

The idea behind this enzyme is that people who react to fructans might eat a wider range of foods such as onions, garlic, asparagus and artichokes instead of staying on a restrictive elimination diet, since strict low-FODMAP diets can cut out nutritious foods. That is a hope, not a finding: no trial has shown that taking this enzyme lets anyone tolerate these foods better. Wheat is a special case, because a fructan enzyme does nothing to gluten and does not make wheat safe in coeliac disease.

Non-genetically modified, wild-type enzyme

This is a sourcing detail rather than a health benefit. The enzyme is made by a wild-type, non-genetically-modified microbial strain, which some shoppers prefer, while many other enzyme makers use genetically modified production strains. Non-GMO sourcing does not make an enzyme work better or make it more likely to ease symptoms.

Untested idea: pairing with alpha-galactosidase

This is a suggestion for future product development, not something you can rely on. The trial authors mentioned that a fructan enzyme might one day be paired with alpha-galactosidase, the enzyme used in products for beans, so that two FODMAP groups are covered at once. No such combination has been tested in people, and this enzyme has not been shown to relieve any symptom on its own.

Mechanism of action

1

Fructan glycosidic bond cleavage

Fructanase enzymes cleave the β-2,1 and β-2,6 glycosidic bonds in fructans — breaking the polysaccharide chains into shorter fructo-oligosaccharides and free fructose. The shorter products are more readily absorbed in the small intestine or less fermentable in the colon. This is the proposed mechanism only; it has not been shown to translate into fewer symptoms in any human trial.

2

Inulin (long-chain fructan) digestion

Inulin is a specific long-chain fructan with chicory root as a primary source. Often added as 'prebiotic fiber' to supplements and functional foods. Added inulin can cause gas and bloating in people who are sensitive to fructans. In laboratory conditions this enzyme breaks down inulin as well as the fructans found naturally in food, but whether that changes how anyone feels has not been tested.

3

Reduced colonic fermentation

Undigested fructans pass into the colon where they're fermented by gut bacteria — producing gas (CO2, hydrogen, methane) and short-chain fatty acids. While SCFAs are beneficial, the gas production causes bloating, distension, and discomfort in sensitive individuals. The idea is that pre-digesting fructans leaves less material for the colon to ferment, but no published human study has measured whether this enzyme actually reduces gas production or fermentation.

4

Stomach and small intestine activity

The manufacturer describes the enzyme as tolerating stomach acid and staying active in the small intestine, which is where dietary fructans arrive. None of the three references on this page measured how much of a meal's fructan content the enzyme actually breaks down inside a person, so treat this as a manufacturer description rather than a demonstrated effect.

Clinical trials

1
Fructanase Phase I Safety and Tolerability Trial

Randomized, double-blind, placebo-controlled safety and tolerability trial of 2,000 inulinase units a day (one 400 mg capsule twice daily) versus placebo for 4 weeks, following a 2-week placebo run-in. Its main measurements were safety markers: blood chemistry, blood counts, blood fats, hsCRP, insulin, lactate and uric acid, alongside a standard digestive symptom questionnaire. Published in Gastro Hep Advances in 2024 (PMID 39318719).

60 healthy adults aged 20 to 65 with no diagnosed digestive problems were enrolled and 58 completed the 4-week study. Nobody with digestive symptoms was included.

The enzyme was safe and well tolerated, and there was no significant difference in digestive outcomes compared with placebo. The researchers pointed out that the participants were healthy adults whose baseline symptoms were minimal, so a symptom difference would not be expected. This was a study of harm, not of benefit. It is the only trial of this ingredient, and it did not show the enzyme relieving anything. Studies in people who actually have fructan-related symptoms have not been done.

2
Regulatory filing (not a clinical trial): FDA New Dietary Ingredient Notification

This entry is not a study of any kind. It is a paperwork submission: a safety dossier filed with the FDA as a New Dietary Ingredient Notification, prepared with the help of a regulatory consultancy. No one was enrolled and no health outcome was measured in people.

No participants. Nothing was measured in people.

The FDA did not object to the notification, which allows the ingredient to be sold in US supplements. That is a legal clearance about safety paperwork. It is not FDA approval, and it is not evidence of any health effect.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; Phase I safety trial documented no adverse effects vs placebo.
Mild GI effects rare.
Important if you have coeliac disease: this enzyme breaks down fructans, which are carbohydrates. Gluten is a protein and the enzyme does nothing to it. Taking it does not make wheat, barley or rye safe for anyone with coeliac disease or a wheat allergy.
Digestive symptoms deserve proper assessment. New or worsening symptoms, unintended weight loss, bleeding or anaemia should be checked by a clinician rather than managed with an enzyme supplement.
Microbial enzyme source — relevant for those with severe mold allergies; though purified preparations should not contain allergenic proteins.
Pregnancy and lactation: digestive enzymes generally considered safe; consult clinician.
This is a food enzyme, not a treatment for IBS or any other diagnosed condition. Talk to your clinician about ongoing digestive symptoms.
No trial has tested whether this enzyme helps people who actually have symptoms, so any benefit is unproven.

Important Drug interactions

Other digestive enzymes such as alpha-galactosidase or lactase: no known interaction, but enzyme combinations have not been tested for benefit in any trial cited here.
Probiotics — complementary; some probiotics may produce fructanase as part of normal microbial activity.
Low-FODMAP diet: there is no evidence that this enzyme lets you reintroduce fructan-containing foods, so do not use it to loosen a diet your clinician or dietitian set up.
Antacids and PPIs — may affect enzyme activity in stomach; timing considerations.
Anticoagulants — minimal interaction concern.
Pregnancy and lactation: consult clinician.
Medicines prescribed for digestive conditions: an enzyme supplement is not a substitute for prescribed treatment, and there is no evidence it adds to one. Check with your prescriber before adding it.

Frequently asked questions about OPTIZIOME® Fructanase® (Inulinase Enzyme for FODMAP Support — BIO-CAT)

What is OPTIZIOME Fructanase?

Optiziome® Fructanase® (formerly Optiziome® Inulinase) is BIO-CAT's fructanase enzyme designed to help digest fructans — a class of FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) found in many vegetables, grains, and fruits that cause digestive discomfort in sensitive individuals.

What is OPTIZIOME Fructanase used for?

OPTIZIOME Fructanase is researched primarily for Gut Health. Fructans are a specific Fodmap class commonly shared across many fruits and vegetables — including wheat, onions, garlic, asparagus, artichokes, and chicory root.

What is the recommended dosage of OPTIZIOME Fructanase?

The clinically studied dose is 400 mg twice daily (2,000 inulinase units a day). This is the dose used in the single 4-week safety trial in healthy adults; no dose has been shown to relieve symptoms. Always follow the product label and check with a healthcare provider for personal advice.

Is OPTIZIOME Fructanase safe, and does it have side effects?

For most healthy adults, OPTIZIOME Fructanase is well tolerated at studied doses. Reported effects can include: Generally well-tolerated; Phase I safety trial documented no adverse effects vs placebo. Mild GI effects rare. It may also interact with some medications. OPTIZIOME Fructanase is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does OPTIZIOME Fructanase interact with any medications?

Possible interactions include: Other digestive enzymes such as alpha-galactosidase or lactase: no known interaction, but enzyme combinations have not been tested for benefit in any trial cited here. Probiotics — complementary; some probiotics may produce fructanase as part of normal microbial activity. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for OPTIZIOME Fructanase?

NutraSmarts rates the evidence for OPTIZIOME Fructanase as Preliminary (1 out of 5). It is backed by 2 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Garvey SM, LeMoire A, Wang J, Lin L, Sharif B, Bier A, Boyd RC, Baisley J Safety and Tolerability of Microbial Inulinase Supplementation in Healthy Adults: A Randomized, Placebo-Controlled Trial Gastro Hep Adv. 2024;3(7):920-930. doi: 10.1016/j.gastha.2024.05.013.PubMedUsed to support: Safety and tolerability trial of this branded enzyme in healthy adults. It supports the safety statements only. It found no significant difference in digestive outcomes versus placebo, so it does not support any claim about IBS, FODMAP sensitivity or symptom relief.
  2. Muir JG, Varney JE, Ajamian M, Gibson PR Gluten-free and low-FODMAP sourdoughs for patients with coeliac disease and irritable bowel syndrome: A clinical perspective International Journal of Food Microbiology. 2019;290:237-246. doi: 10.1016/j.ijfoodmicro.2018.10.016.PubMedUsed to support: Not a trial and not a study of this enzyme. It is a review and clinical perspective on using sourdough cultures in breadmaking to lower the fructan content of bread. It offers background on why fructans matter to some people, and nothing more.
  3. Potter MD, Duncanson K, Jones MP, Walker MM, Keely S, Talley NJ Wheat Sensitivity and Functional Dyspepsia: A Pilot, Double-Blind, Randomized, Placebo-Controlled Dietary Crossover Trial with Novel Challenge Protocol Nutrients. 2020;12(7):1947. doi: 10.3390/nu12071947.PubMedUsed to support: A small pilot crossover trial of a diet, not of this enzyme, in people with functional dyspepsia. It was negative: the gluten-free low-FODMAP diet produced an overall improvement that was not statistically significant, and a specific food trigger could not be reliably demonstrated. It does not support any claim on this page.